Accelerated atherosclerosis: An extraarticular feature of rheumatoid arthritis?

Arthritis and Rheumatism

Volumn 46, Issue 4, 2002, Pages 862-873

  Van Doornum, S ^a   McColl, G ^b   Wicks, I P ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; CORTICOSTEROID; CYCLOSPORIN; HOMOCYSTEINE; LIPID; METHOTREXATE;

ATHEROSCLEROSIS; CAUSE OF DEATH; CHRONIC DISEASE; DISEASE ASSOCIATION; HEART FAILURE; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; IMMUNOPATHOLOGY; INFLAMMATION; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SMOKING; STEROID THERAPY;

ARTERIOSCLEROSIS; ARTHRITIS, RHEUMATOID; HUMANS; RISK FACTORS;

EID: 0036229685     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10089     Document Type: Review

References (129)

1. The pathogenesis of atherosclerosis: A perspective for the 1990s
2. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses
3. Generation of C-reactive protein and complement components in atherosclerotic plaques
4. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states
5. No increased mortality in patients with rheumatoid arthritis: Up to 10 years of follow up from disease onset
6. Mortality in rheumatoid arthritis patients with disease onset in the 1980s
7. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: A study of incidence, prevalence, and mortality
8. Mortality in early "saw-tooth" treated rheumatoid arthritis patients during the first 8-14 years
9. Length of life and cause of death in rheumatoid arthritis
10. Increased mortality among persons with rheumatoid arthritis, but where RA does not appear on death certificate: Eleven-year follow-up of an epidemiological study
11. Increased mortality in rheumatoid arthritis
12. Rheumatoid arthritis and mortality: A longitudinal study in Pima Indians
13. Cause of death in rheumatoid arthritis
14. Longterm mortality outcome in patients with rheumatoid arthritis: Early presenters continue to do well
15. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis
16. The mortality of rheumatoid arthritis
17. Mortality among arthritics
18. Ten year mortality and causes of death in patients with rheumatoid arthritis
19. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden
20. Survival, prognosis, and causes of death in rheumatoid arthritis
21. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992
22. Mortality and survival in rheumatoid arthritis: A 25 year prospective study of 100 patients
23. Mortality in rheumatoid arthritis
24. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years
25. Survivorship and death in rheumatoid arthritis
26. Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine
27. Recent improvements in survival in patients with rheumatoid arthritis: Better outcomes or different study designs?
28. Mortality in rheumatoid arthritis
29. Rheumatology function tests: Grip strength, walking time, button test and questionnaires document and predict longterm morbidity and mortality in rheumatoid arthritis
30. Taking mortality in rheumatoid arthritis seriously: Predictive markers, socioeconomic status and comorbidity
31. Mortality in rheumatoid arthritis: Have we made an impact in 4 decades?
32. Death certificate and mortality in rheumatoid arthritis
33. Causes of death in autopsied RA patients
34. Functional status predicts mortality in a community based rheumatoid arthritis population
35. Factors predicting a poor life prognosis in rheumatoid arthritis: An eight year prospective study
36. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis: A retrospective cohort study from disease onset
37. Mortality predictors among 263 patients with rheumatoid arthritis
38. Occurrence of extra-articular disease manifestations is associated with excess mortality in a population based cohort of patients with rheumatoid arthritis
39. Increased prevalence of cardiovascular and cerebrovascular disease in rheumatoid arthritis compared with osteoarthritis
40. Rheumatoid arthritis is an independent risk factor for ischaemic heart disease
41. Comorbidity in arthritis
42. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults
43. Increased carotid wall thickness in patients with rheumatoid arthritis
44. Progression of atherosclerosis in common carotid artery (CCA) of patients with rheumatoid arthritis (RA): Thickening of intimamedia thickness (IMT) by ultrasonography
45. Smoking, lung function, and rheumatoid factors
46. A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis in female health professionals
47. Lifestyle and the risk of rheumatoid arthritis: Cigarette smoking and alcohol consumption
48. Reproductive factors, smoking, and the risk for rheumatoid arthritis
49. Smoking and risk of rheumatoid arthritis
50. Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis
51. Cigarette smoking increases the risk of rheumatoid arthritis: Results from a nationwide study of disease-discordant twins
52. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: Results from a primary care-based incident case-control study in Norfolk, England
53. Current tobacco smoking, formal education, and the risk of rheumatoid arthritis
54. Heavy cigarette smoking is strongly associated with rheumatoid arthritis (RA), particularly in patients without a family history of RA
55. Cigarette smoking and rheumatoid arthritis severity
56. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis
57. The association of cigarette smoking with disease outcome in patients with early inflammatory polyarthritis
58. Cholesterol and coronary heart disease: Predicting risks by levels and ratios
59. Serum total, HDL, LDL cholesterol, and triglyceride levels in patients with rheumatoid arthritis
60. Dyslipoproteinemia in the course of active rheumatoid arthritis
61. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. I. Relativity to inflammatory activity
62. Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis
63. Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis
64. Lp(a) lipoprotein in cardiovascular disease
65. Lipoprotein(a) and coronary heart disease: Meta-analysis of prospective studies
66. Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis
67. Lipid profiles in untreated patients with rheumatoid arthritis
68. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease-modifying drug treatment
69. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: Reversal of deleterious effects of steroids on lipids
70. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus
71. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis
72. Effects of chloroquine on the dyslipidemia of non-insulin-dependent diabetes mellitus
73. Hydroxychloroquine use in the Baltimore Lupus Cohort: Effects on lipids, glucose and thrombosis
74. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis
75. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort
76. Hyperhomocysteinemia: An independent risk factor for vascular disease
77. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus
78. Increased plasma levels of homocysteine and other thiol compounds in rheumatoid arthritis women
79. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: Implications for cardiovascular disease prevention
80. Serum homocysteine and methylmalonic acid in patients with rheumatoid arthritis and cobalaminopenia
81. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis
82. Abnormal homocysteine metabolism in rheumatoid arthritis
83. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials
84. Impaired glucose handling in active rheumatoid arthritis: Relationship to the secretion of insulin and counter-regulatory hormones
85. Evidence for peripheral impaired glucose handling in patients with connective tissue diseases
86. Intramuscular gold therapy is associated with long survival in patients with rheumatoid arthritis
87. Methotrexate alters the course of rheumatoid arthritis (RA). Increased survival of methotrexate treated RA patients: A 25-year study of 1,842 patients
88. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE
89. Relation of cyclosporine blood levels to adverse effects on lipoproteins
90. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity
91. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
92. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
93. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries
94. Dietary n-3 fatty acids and therapy for rheumatoid arthritis
95. Fish oil and rheumatoid arthritis: Anti-inflammatory and collateral health benefits
96. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial
97. Risk of cardiovascular events associated with selective COX-2 inhibitors
98. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice
99. Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice
100. Induction of neonatal tolerance to oxidized lipoprotein reduces atherosclerosis in ApoE knockout mice
101. Reduction of atherosclerosis in mice by inhibition of CD40 signalling
102. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice
103. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene
104. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992
105. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
106. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
107. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
108. Production of C-reactive protein and risk of coronary events in stable and unstable angina
109. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men
110. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men
111. The role of T cells in rheumatoid arthritis
112. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes
113. Autoantibody against oxidised LDL and progression of carotid atherosclerosis
114. Antibody against oxidized low-density lipoprotein predicting myocardial infarction
115. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction
116. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus
117. Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome
118. Direct proinflammatory effect of C-reactive protein on human endothelial cells
119. Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein
120. Endothelial cell activation by pore-forming structures: Pivotal role for interleukin-1alpha
121. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: Implications for serum amyloid A function
122. Current concepts of the pathogenesis of the acute coronary syndromes
123. A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study
124. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor
125. Von Willebrand factor is an acute phase reactant in man
126. Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1
127. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis
128. Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: An 8 year followup study
129. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels